A common CHRNE mutation in Brazilian patients with congenital myasthenic syndrome
Carregando...
Citações na Scopus
15
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER HEIDELBERG
Autores
SOBREIRA, Claudia Ferreira da Rosa
SANTOS, Andre Cleriston Jose dos
TOMASELLI, Pedro Jose
MARQUES JR., Wilson
ORTEGA, Roberta Paiva Magalhes
COSTA, Marcela Camara Machado
Citação
JOURNAL OF NEUROLOGY, v.265, n.3, p.708-713, 2018
Resumo
The most common causes of congenital myasthenic syndromes (CMS) are CHRNE mutations, and some pathogenic allelic variants in this gene are especially frequent in certain ethnic groups. In the southern region of Brazil, a study found the c.130dupG CHRNE mutation in up to 33% of families with CMS. Here, we aimed to verify the frequency of this mutation among individuals with CMS in a larger cohort of CMS patients from different areas of Brazil and to characterize clinical features of these patients. Eighty-four patients with CMS, from 72 families, were clinically evaluated and submitted to direct sequencing of the exon 2 of CHRNE. The c.130dupG mutation was found in 32 patients (23 families), with 26 patients (19 families, 26.3%) in homozygosis, confirming its high prevalence in different regions of Brazil. Among the homozygous patients, the following characteristics were frequent: onset of symptoms before 2 years of age (92.3%), little functional restriction (92.3%), fluctuating symptoms (100%), ocular muscle impairment (96.1%), ptosis (100%), limb weakness (88.4%), response to pyridostigmine (100%), facial involvement (77%), and bulbar symptoms (70.8%). The pretest probability of finding at least one allele harbouring the c.130dupG mutation was 38.1%. Selecting only patients with impaired eye movement together with limb weakness and improvement with pyridostigmine, the probability increases to 72.2%. This clinical pre-selection of patients is likely a useful tool for regions where CHRNE mutations have a founder effect. In conclusion, the CHRNE mutation c.130dupG leads to fairly benign natural course of the disease with relative homogeneity.
Palavras-chave
Congenital myasthenic syndrome, Neuromuscular junction, CHRNE, Acetylcholine receptor, Pyridostigmine
Referências
- Neto OA, 2017, CAN J NEUROL SCI, V44, P125, DOI 10.1017/cjn.2016.322
- Abicht A, 1999, NEUROLOGY, V53, P1564, DOI 10.1212/WNL.53.7.1564
- Abicht A, 2003, GENEREVIEWS, P1993
- Abicht A, 2012, HUM MUTAT, V33, P1474, DOI 10.1002/humu.22130
- Aharoni S, 2017, NEUROMUSCULAR DISORD, V27, P136, DOI 10.1016/j.nmd.2016.11.014
- Barisic N, 2002, NEUROPEDIATRICS, V33, P249, DOI 10.1055/s-2002-36738
- Beeson David, 2005, Neuromuscul Disord, V15, P498, DOI 10.1016/j.nmd.2005.05.001
- Burke G, 2004, NEUROMUSCULAR DISORD, V14, P356, DOI 10.1016/j.nmd.2004.03.005
- Croxen R, 2002, NEUROLOGY, V58, P1563, DOI 10.1212/WNL.58.10.1563
- Engel AG, 2015, LANCET NEUROL, V14, P420, DOI 10.1016/S1474-4422(14)70201-7
- Finlayson Sarah, 2013, Pract Neurol, V13, P80, DOI 10.1136/practneurol-2012-000404
- McMacken G, 2017, NEUROPEDIATRICS, V48, P294, DOI 10.1055/s-0037-1602832
- Mihaylova V, 2010, J NEUROL NEUROSUR PS, V81, P973, DOI 10.1136/jnnp.2009.177816
- Mihaylova V, 2008, BRAIN, V131, P747, DOI 10.1093/brain/awm325
- Muller JS, 2003, NEUROLOGY, V60, P1805, DOI 10.1212/01.WNL.0000072262.14931.80
- Natera-de Benito D, 2017, NEUROMUSCULAR DISORD, V27, P1087, DOI 10.1016/j.nmd.2017.08.003
- Natera-de Benito D, 2016, NEUROMUSCULAR DISORD, V26, P789, DOI 10.1016/j.nmd.2016.08.005
- Ohno K, 1996, NEURON, V17, P157, DOI 10.1016/S0896-6273(00)80289-5
- Ohno K, 1998, ANN NEUROL, V44, P234, DOI 10.1002/ana.410440214
- Cruz PMR, 2015, NEUROLOGY, V85, P1043, DOI 10.1212/WNL.0000000000001952